Thrombosed AV grafts

Arteriovenous (AV) access grafts that have thrombosed are often associated with worse outcomes than those that are stenosed1

  • The 2006 KDOQI guidelines for vascular access specify reasonable goals as follows2:
    • Stenosed grafts: 50% primary patency at six months 
    • Thrombosed grafts: 40% primary patency at three months

There are a limited number of randomized trials to help guide evidence-based treatment decisions for patients with thrombosed grafts

  • In the Gore REVISE Clinical Study, 43% of patients in the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface* arm of the study enrolled with a thrombosed graft.1 
An end-stage renal disease patient with recurrent thrombosis and stenosis of ePTFE grafts.

Before

Images courtesy of Daniel V. Patel, M.D. Used with permission.

Read the full case study

An 8 mm x 5 cm GORE® VIABAHN® Device placed at the venous anastomosis.

After

Images courtesy of Daniel V. Patel, M.D. Used with permission.

Read the full case study

The GORE® VIABAHN® Device has proven success when treating thrombosed grafts1,2 

Proven patency

  • Exceeded KDOQI minimum guidelines for three-month circuit primary patency for thrombotic patients (48%) whereas Percutaneous Transluminal Angioplasty (PTA) did not (39%)1,2
  • Increased primary patency in thrombosed grafts of both the target lesion and the circuit by ~50% when compared to PTA at six months1

Fewer reinterventions

  • Lowered the mean number of interventions over two years by 40% in thrombosed grafts3

* As used by Gore, PROPATEN Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.

  1. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. Journal of Vascular Surgery 2016;64(5):1400-1410.e1. http://www.sciencedirect.com/science/article/pii/S0741521416301756
  2. Kidney Disease Outcomes, Quality Initiative (KDOQI). Clinical Practice Guidelines and Clinical Practice Recommendations. 2006 Updates. National Kidney Foundation Web site. https://www.kidney.org/sites/default/files/docs/12-50-0210_jag_dcp_guidelines-hd_oct06_sectiona_ofc.pdf . Accessed July 17, 2018.
  3. Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators.  Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial.  Journal of Vascular & Interventional Radiology 2019;30(2):203-211.e4.

eIFU Symbol

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

241355851-EN

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.